Analysis of differentiation of antiEGFR antibody in the 1st line chemotherapy with mFOLFOX6 in RAS-wild metastatic colorectal cancer.

Analysis of differentiation of antiEGFR antibody in the 1st line chemotherapy with mFOLFOX6 in RAS-wild metastatic colorectal cancer. - Differentiation of cetuximab and panitumumab in 1st line chemotherapy of RAS-wild mCRC.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031535

Enrollment

Registered

2018-04-01

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

mFOLFOX6+cetuximab or panitumumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pathologically proven colorectal cancer RAS wild type PS; 0-2 untreated case

Exclusion criteria

Exclusion criteria: severe dysfunctions of vital organs no prior radiotherapy, chemotherapy no other co-existing malignancy within the last five years no severe concurrent medical or psychiatric illnessno hypersensitivity to the study drugs

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
safety relapse-free survival overall survival early tumor shurinkage neutrophil to lymphocyte ratio	—

Countries

Japan

Contacts

Public ContactDai Manaka

Kyoto Katsura Hospital Department of Surgery, Gastro-Intestinal Center

d_manaka@katsura.com075-391-5811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026